28 02, 2024

TAmiRNA is hiring

2024-02-28T08:44:59+01:00February 28th, 2024|biomarker, biomarkers, microRNAs, NGS|0 Comments

We are hiring. We cannot wait to meet you to share our passion in Transcriptomics! Interested candidates should email a cover letter and resume to karriere@tamirna.com

10 01, 2024

TAmiRNA partners with Techtum Lab

2024-01-10T09:45:03+01:00January 10th, 2024|microRNA, microRNA services, microRNAs, miND spike ins, NGS, PCR testing service, smallRNA, Techtum Lab|Comments Off on TAmiRNA partners with Techtum Lab

TAmiRNA has entered an exclusive distribution agreement with Techtum Lab for the sales of their products in the Nordics. Techtum Lab is a full service supplier and partner to clinical and research molecular biology laboratories and looks back at >45 years of experience in the Nordic region. TAmiRNA complements Techtum’s NGS portfolio with the miND Spike-Ins, a unique set of controls for small RNA sequencing experiments. Furthermore, Techtum partners with TAmiRNA to make customized RNA sequencing services accessible to those customers who are looking for external support with analysing their sample’s RNA content.

22 11, 2023

TAmiRNA meets Japanese Pharma to present microRNA Biomarker Discovery Solutions

2023-11-22T11:22:16+01:00November 22nd, 2023|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, NGS, PCR testing service, SPI|Comments Off on TAmiRNA meets Japanese Pharma to present microRNA Biomarker Discovery Solutions

Matthias Hackl, CEO/CSO of TAmiRNA, visited Japan between November 11th and 18th to join Summit Pharmaceutical international to introduce TAmiRNA to 12 medium- and large-size pharmaceutical companies. Matthias presented information on microRNA and mRNA biomarker discovery in liquid biopsies using TAmiRNA´s unique miND® pipeline for absolute quantification of microRNAs. In addition, Matthias joined a seminar on “Manufacturing and omic-based characterization of extracellular vesicles as drug products” organized by the local partner Summit Pharmaceutical International. In his talk, Matthias explained to >70 representatives from Japanese Universities and Pharmaceutical industry TAmiRNA’s the advantages of full molecular characterization of exosomes and extracellular vesicles (EVs) to determine EV composition, consistency, and mode-of-action.

9 10, 2023

TAmiRNA at Extracellular Vesicles Forum

2023-10-09T11:28:13+02:00October 9th, 2023|biomarker, biomarkers, extracellular vesicle, microRNAs, NGS, smallRNA|Comments Off on TAmiRNA at Extracellular Vesicles Forum

TAmiRNA Scientific Consultant Magdalena Mecking is attending the Extracellular Vesicles Forum on Oct 10th – 11th in Cambridge. Stop by one of her posters and learn more about how TAmiRNA’s service may benefit your EV project! Reach out to Magdalena directly and discuss our latest developments and how TAmiRNA's  services can assist your business!

21 09, 2023

Unique miRNome and transcriptome profiles underlie microvascular heterogeneity in mouse kidney

2023-09-21T11:12:47+02:00September 21st, 2023|biomarker, biomarkers, LMD, microRNA services, microRNAs, microstructure, NGS, Vivomicx|Comments Off on Unique miRNome and transcriptome profiles underlie microvascular heterogeneity in mouse kidney

We want to draw your attention to our latest publication which appeared in American Journal of Physiology-Renal Physiology. We could show that laser microdissection combined with (small) RNA sequencing revealed renal microvascular compartment-specific miRNA and mRNA expression profiles. Unique miRNome and transcriptome profiles underlie microvascular heterogeneity in mouse kidney Luxen M, Zwiers PJ, Meester F et al. Am J Physiol Renal Physiol. 2023 Sep 1;325(3):F299-F316. doi: 10.1152/ajprenal.00005.2023. Epub 2023 Jul 6. TAmiRNA and Dutch company Vivomicx have combined their respective technologies of high sensitivity gene expression profiling (RT-qPCR and smallRNAseq/RNAseq) and laser microdissection to enable cell-type specific and space-resolved RNA expression analysis in complex tissues. Click here to learn more about this service

1 09, 2023

TAmiRNA at RNA Leaders conference

2023-09-01T10:45:52+02:00September 1st, 2023|biomarker, biomarkers, microRNAs, NGS|Comments Off on TAmiRNA at RNA Leaders conference

TAmiRNA CEO/CSO Matthias Hackl will attend the RNA Leaders conference in Boston next week to speak about how cell-free RNA biomarkers can be incorporated in pre-clinical and clinical development to inform about drug safety, drug targeting, and drug efficacy. Reach out to Matthias directly to meet with him before or after his presentation on Thursday, Sept. 7th at 4:30 pm ET and discuss our latest developments and how TAmiRNA's  services can assist your business!

7 06, 2023

TAmiRNA presenting miND® NextGen sequencing opportunities at ISSX/DMDG 2023 Meeting

2023-06-07T10:36:35+02:00June 7th, 2023|biomarker, biomarkers, microRNAs, NGS|Comments Off on TAmiRNA presenting miND® NextGen sequencing opportunities at ISSX/DMDG 2023 Meeting

TAmiRNA will be a significant contributor to the inaugural joint European meeting of the ISSX and DMDG respectively focused on xenobiotics and drug metabolics. Dr. Matthias Hackl, CEO and co-founder, will take part in the discussions of Symposium 4: ‘MicroRNAs as Biomarkers of Clinical Drug-induced Organ Injury’ (Tuesday, June 13, 1000-1200 hrs). Dr. Hackl’s presentation ‘miRNA Biomarker Development: Pitfalls and Best Practices for Discovery and Validation’ will highlight the increasing scope to apply TAmiRNA’s recently developed MicroRNA Next-Generation Sequencing Discovery (miND®) technology and associated miND® spike-ins to identify novel circulating microRNA biomarkers of CNS and other organ damage, as well as comparative characterization and absolute quantitation of small RNAs associated with RNA-induced silencing complexes (RISCs). Take advantage, [...]

26 05, 2023

TAmiRNA at RNA Society Annual Meeting, 30 May – 4 June 2023, Singapore

2023-05-26T08:23:02+02:00May 26th, 2023|biomarker, biomarkers, microRNAs, NGS|Comments Off on TAmiRNA at RNA Society Annual Meeting, 30 May – 4 June 2023, Singapore

TAmiRNA Senior Scientist Dr. Kseniya Khamina-Kotisch will present Poster 46 ‘Identification of novel circulating MicroRNA Biomarkers of Central Nervous System Damage by absolute quantitation using a MicroRNA Next-Generation Sequencing Discovery (miND) Assay’. She will also present Poster 66: ‘Comparative characterization and absolute quantitation of small RNAs associated with RNA-induced silencing complexes (RISCs) in cells, plasma, urine, and extracellular vesicles’. Take advantage, meet Kseniya and discuss our latest developments and how TAmiRNA's miND spike ins and services can assist your business!

17 01, 2023

Biogenity Joins Forces with TAmiRNA

2023-03-10T08:29:26+01:00January 17th, 2023|biomarkers, diagnose disease, microRNA, NGS, smallRNA, treatment monitoring|Comments Off on Biogenity Joins Forces with TAmiRNA

The collaboration between Biogenity and TAmiRNA is a big step towards further enabling our clients to identify new biomarkers that can be used to diagnose disease, monitor treatment response, and predict patient outcomes. And an important step to advance omics research and bring better healthcare to future generations. click here to read the press release

28 10, 2022

miND spike-in

2023-03-10T10:13:11+01:00October 28th, 2022|microRNA, NGS, smallRNA|Comments Off on miND spike-in

TAmiRNA has launched an innovative NGS technology for absolute quantitation of miRNAs and other small RNAs , the miND® (microRNA Next-Generation Sequencing Discovery) spike-in. The miND® spike-in has been developed for small RNA sequencing experiments and absolute quantitation of microRNAs in any biological matrix and species, overcoming previous challenges of quality control and difficulty in achieving  absolute quantitation of miRNAs across different biological matrix and species. click here for more Information on the miND spike-ins

Go to Top